Where This Peptide Ranking Comes From

Dr. Alex Tatem is a board-certified urologist who sat down and ranked every major peptide from S-tier (best of the best) to F-tier (outright failures). His video pulled in over 84,000 views. And for good reason — he's not selling anything, he's sharing clinical experience.

We at Peptex took his ranking, cross-referenced it with other physicians, and added our own practical commentary. If something doesn't work, we'll say so. That's the deal.

S-Tier: Peptides That Actually Change the Game

[[Retatrutide|11]] — The Only GLP-1 at the Top

Triple agonist. GLP-1, GIP, and glucagon — three mechanisms instead of one. In trials, participants lost an average of 24.2% body weight over 48 weeks. But here's the kicker: fat loss exceeded what caloric restriction alone could explain. The drug doesn't just suppress appetite. It rewires metabolism.

No other GLP-1 agonist made S-tier in Tatem's ranking. [[Tirzepatide|10]] is solid, but [[Retatrutide|11]] operates in a different league thanks to that third component — glucagon.

[[PT-141|19]] (Bremelanotide) — Works Through the Brain, Not Blood Vessels

Viagra dilates blood vessels. [[PT-141|19]] takes a completely different route — melanocortin receptors in the limbic system. Put simply, it works at the level of desire, not mechanics. And it kicks in within minutes.

Side effects exist: nausea (especially early on) and skin darkening with prolonged use. But for people who haven't responded to standard therapies, this can be the one thing that actually delivers.

Growth Hormone — The Gold Standard

No surprises here. Growth hormone sits at the top of the somatotropic pathway. Every secretagogue out there is basically an attempt to get your body producing GH on its own. Sometimes that makes sense (cheaper, gentler). But in terms of raw effectiveness, direct GH beats all of them.

A-Tier: One Peptide, But What a Peptide

[[GHK-Cu|24]] — Universally Positive Doctor Reviews

Tatem pointed out something striking: [[GHK-Cu|24]] is the only peptide where he hasn't heard a single negative review from colleagues. Not one. That's rare in a space where opinions split on virtually everything.

Topical data (creams, serums) is strong. Skin, hair, anti-aging — all well-supported. Injectable data from large trials is thinner, but anecdotal physician reports are consistently positive.

Here's what makes it stand out: patients notice results on their own. No one has to explain that it's working. Skin looks better, and other people confirm it. That kind of visible outcome builds real confidence in a peptide.

B-Tier: Solid Options With Caveats

[[Tesamorelin|18]] — A GHRH Analog That Actually Works

[[Tesamorelin|18]] is one of the few peptides with serious clinical data behind visceral fat reduction. It's a growth hormone releasing hormone analog, effective for lipodystrophy. One problem: the pharmaceutical version costs a fortune.

But the mechanism works, and this isn't theory — there's real human data. If it weren't for the price tag, it could arguably sit a tier higher.

[[NAD+|14]] — Safe, But the Evidence Is Still Building

[[NAD+|14]] is a coenzyme involved in hundreds of cellular reactions. Reduces oxidative stress, supports mitochondrial function. Safety profile is clean.

Large-scale clinical trials, though? Still scarce. It's widely used in anti-aging practice, plenty of doctors prescribe it, and patients report improved energy and cognitive function. But Tatem honestly placed it at B-tier because the big data isn't there yet.

IGF-1 LR3 — Real Hypertrophy, With a Catch

The only next-generation peptide that genuinely stimulates muscle tissue growth. Not indirectly through GH, but directly. Sounds great. But the side effect is serious — blood sugar drops. You cannot use this without glucose monitoring.

C-Tier: More Promise Than Proof

[[BPC-157|22]] — Cult Status, 50/50 Reviews

[[BPC-157|22]] is probably the most popular recovery peptide out there. Rat data looks promising: tendon healing, joint repair, GI protection. The problem? No human trials to date.

Doctor and patient reviews split right down the middle. Half say it's fantastic. The other half noticed nothing. The pattern seems to be that people with active injuries or inflammation get better results than those using it preventively.

Safety profile is clean, though. And when a peptide might help and won't hurt, trying it makes sense.

[[TB-500|25]] — Same Story, Often Paired

Situation mirrors [[BPC-157|22]]. Limited human data, mixed anecdotal reports. Often stacked together as the "Wolverine stack." The logic: two healing mechanisms beat one. But the evidence base for the combo also remains at the anecdotal level.

[[GLOW|23]] (BPC + TB + GHK Stack) — Only as Strong as the Weakest Link

Tatem made a fair point: any stack is only as good as its weakest component. [[GLOW|23]] combines [[BPC-157|22]], [[TB-500|25]], and [[GHK-Cu|24]]. GHK-Cu sits at A-tier. The other two are C-tier. So the stack lands at C.

That doesn't make the stack useless. It means you shouldn't expect magic just because there are three ingredients.

D-Tier: Yesterday's Options

[[Ipamorelin|17]] — An Outdated GH Secretagogue

[[Ipamorelin|17]] used to be the standard pick for growth hormone stimulation. Does it work? Yes, but mildly. The issue is that better options have emerged — both in stimulation strength and action profile.

If someone recommends ipamorelin as a top GH peptide today, it's worth asking why not something more current.

F-Tier: Failures and Contested Candidates

[[AOD-9604|16]] — The Paradox With Clinical Data

This one is interesting. Most peptides land in lower tiers because data is missing. With [[AOD-9604|16]], the situation is reversed: clinical trials exist, and they're well-designed. The result of those trials? The drug doesn't work.

That's the paradox. AOD-9604 marketing leans on the growth hormone fragment angle and fat-burning promises. But the data says: no meaningful effect. When quality studies produce a negative result, that's actually stronger evidence than having no data at all.

[[Epithalon|15]] — Interesting Mechanism, Complicated Reality

[[Epithalon|15]] targets telomerase — an enzyme linked to cellular aging. The mechanism looks elegant on paper. But real data is thin, and it's the number one candidate for counterfeiting due to manufacturing complexity.

However, physician opinions diverge here. Another specialist, Quinn Stillson MD, ranks epithalon second in his longevity list. His argument: mouse studies showed 11-31% lifespan extension. Those are meaningful numbers, even in an animal model.

Our position: we carry [[Epithalon|15]] because demand exists and the mechanism is promising. But we recommend treating it as an experimental option, not a proven solution.

Which Peptide Is Best: The Peptex Perspective

We don't just resell everything. Our catalog is built on a balance between data, doctor reviews, and real demand. Here's our logic:

• [[Retatrutide|11]] and [[Tirzepatide|10]] — for serious weight management. They work.
• [[GHK-Cu|24]] — best choice for skin and anti-aging. The unanimous doctor reviews confirm it.
• [[PT-141|19]] — unique mechanism, nothing else like it.
• [[BPC-157|22]] and [[TB-500|25]] — we carry them because the safety profile is solid and the recovery potential is real. We're honest: human data is insufficient.

All peptides are stored in lyophilized form. After reconstitution, shelf life is 90 days when refrigerated. Factor this into your course planning.

Why Honesty Beats Marketing

We could have left out the negatives. Could have skipped the part about [[AOD-9604|16]] failing in trials. Could have glossed over [[BPC-157|22]] reviews being split down the middle. But what's the point?

Peptides aren't magic pills. Some work brilliantly, and doctor rankings confirm it. Others work okay, with caveats. And some just don't deliver. When a seller is honest about what fails, their recommendations about what works become trustworthy.

If you have questions about picking the right peptide for your specific goal — reach out to our team. We'll match you based on data, not hype.